A clinical trial has shown that the immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk.
A clinical trial has shown that the immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk.